 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IMC002 / Immuneoncia Therap, amulirafusp alfa (IMM0306) / ImmuneOnco Biopharma
Evaluating the Influence of IMC-002, a Novel Anti-CD47 Monoclonal Antibody, on Pretransfusion Compatibility Testing (342) - Oct 8, 2024 - Abstract #AABB2024AABB_56;
Plasma spiked with IMC-002 showed concentration-dependent panreactive results in antibody screening tests. However, it is presumed that these interferences are caused by mechanisms other than typical antigen-antibody reactions.
- IMC002 / Immuneoncia Therap
Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors. (Hall A; Poster Bd #: 121) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3043;
P1
IMC-002 monotherapy demonstrates meaningful clinical benefits in refractory HCC. The density of CD47+macrophages analyzed by AI is higher in CBR patients.
- || IMC002 / Immuneoncia Therap
Trial completion, Enrollment change, Metastases: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (clinicaltrials.gov) - Apr 12, 2024
P1, N=12, Completed, Sponsor: ImmuneOncia Therapeutics Inc.
The density of CD47+macrophages analyzed by AI is higher in CBR patients. Recruiting --> Completed | N=24 --> 12
- || IMC002 / Immuneoncia Therap
Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy (clinicaltrials.gov) - Apr 11, 2024
P1, N=49, Recruiting, Sponsor: ImmuneOncia Therapeutics Inc.
Recruiting --> Completed | N=24 --> 12 N=24 --> 49 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jul 2024 --> Jun 2025
- IMC002 / Immuneoncia Therap
Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2568;
P1
Conclusions IMC-002 demonstrated a favorable safety profile when administered intravenously every 2 weeks up to 30 mg/kg and showed preliminary efficacy in patients with advanced solid tumors. Based on safety and PK profile, we determined the recommended phase 2 dose as 20 mg/kg.
- || IMC002 / Immuneoncia Therap
Enrollment open, Metastases: A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy (clinicaltrials.gov) - Jun 5, 2022
P1, N=24, Recruiting, Sponsor: ImmuneOncia Therapeutics Inc.
Based on safety and PK profile, we determined the recommended phase 2 dose as 20 mg/kg. Not yet recruiting --> Recruiting
- || IMC002 / Immuneoncia Therap
New P1 trial, Metastases: A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy (clinicaltrials.gov) - Mar 10, 2022
P1, N=24, Not yet recruiting, Sponsor: ImmuneOncia Therapeutics Inc.
- IMC002 / Immuneoncia Therap
[VIRTUAL] A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer () - Oct 14, 2020 - Abstract #SITC2020SITC_1254;
The purpose of the study is to assess the safety and tolerability of IMC-002 and determine the recommended Phase 2 dose (RP2D) of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. Ethics Approval All experimental procedures were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the contract research organizations.
- IMC002 / Immuneoncia Therap
[VIRTUAL] A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer () - Oct 14, 2020 - Abstract #SITC2020SITC_519;
The purpose of the study is to assess the safety and tolerability of IMC-002 and determine the recommended Phase 2 dose (RP2D) of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. Ethics Approval All experimental procedures were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the contract research organizations.
- || IMC002 / Immuneoncia Therap
Enrollment open, Metastases: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (clinicaltrials.gov) - May 26, 2020
P1, N=24, Recruiting, Sponsor: ImmuneOncia Therapeutics Inc.
Ethics Approval All experimental procedures were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the contract research organizations. Not yet recruiting --> Recruiting
- IMC002 / Immuneoncia Therap
[VIRTUAL] A PRECLINICAL STUDY OF IMC-002, A FULLY HUMAN THERAPEUTIC ANTIBODY SAFELY TARGETING CD47 IN CANCER () - May 16, 2020 - Abstract #EHA2020EHA_2344;
The first-in-human (FIH) study of IMC-002 is planned to be initiated during the 1st half of 2020. The purpose of the study is to assess the safety and tolerability of IMC-002 and determine the recommended Phase 2 dose (RP2D) of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.
- || IMC002 / Immuneoncia Therap
IND: #SamsungBiologics and #ImmuneOnciaTherapeutics Inc. Development and Manufacturing Agreement Accomplishes #InvestigationalNewDrug Clearance of #IMC002 (#AntiCD47Antibody) https://t.co/3ItuFriVWD (Twitter) - Apr 26, 2020
- || IMC002 / Immuneoncia Therap
New P1 trial, Metastases: A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (clinicaltrials.gov) - Mar 12, 2020
P1, N=24, Not yet recruiting, Sponsor: ImmuneOncia Therapeutics Inc.